D3 receptor Inhibitors
2 drugsAbout D3 receptor
The D3 receptor is a dopamine receptor family member and GPCR primarily located in the brain. It modulates neuronal activity and is implicated in various central nervous system (CNS) processes.
The D3 receptor is a therapeutic target despite the lack of genetic evidence directly linking it to specific diseases. Two FDA-approved drugs targeting this receptor highlight its therapeutic potential in CNS disorders and other indications.
Two approved drugs, BARHEMSYS and ONAPGO, target the D3 receptor, both of which are small molecules. ACACIA and MDD US are the companies marketing these drugs.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Postoperative Pain Management with only 2 trials.
Top D3 receptor Drugs
ACACIA and MDD US are the only two companies with approved drugs targeting the D3 receptor.
Low market concentration suggests relatively low barriers to entry for new competitors.
D3 receptor Drug Modality Landscape
Modalities
Routes of Administration
D3 receptor is druggable by small molecules, though no oral formulations are currently approved.
The lack of diverse modalities represents a whitespace opportunity for novel biologics targeting the D3 receptor.
D3 receptor Clinical Trials 32 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 6 | 0 | 0 | 100% |
| Phase 2 | 5 | 1 | 1 | 2 | 50% |
| Phase 3 | 7 | 5 | 1 | 1 | 83% |
| Phase 4 | 14 | 12 | 2 | 0 | 86% |
Top Sponsors
By Modality
Top Conditions
D3 receptor Drug Approval Timeline (2020 - 2025)
The first drug targeting the D3 receptor was approved in 2020, with the most recent approval in 2025.
Recent approval suggests renewed interest in the target, but further approvals are needed to confirm an upward trend.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 149 clinical trials targeting D3 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities